I have experience in clinical care, quality assurance & patient safety, prostate cancer, clinical trials, facilitating RTOG/NRG Oncology investigator research, drug development, entrepreneurship, preclinical model systems, biomarker analysis, and mentorship.
Our group defined for prostate brachytherapy the influence of edema on dosimetric parameters critical for quality metrics, with more recent research correlating radiotherapy protocol deviations and overall survival (JNCI, 2012).
Our work funded by the Department of Defense (DoD) and the Prostate Cancer Foundation focuses on the “self-seeding” of prostate cells with metastatic properties back to the site of origin, contributing to disease progression.